Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Blood

Volumn 114, Issue 3, 2009, Pages 535-546

  Johnson, Laura A ^a,d   Morgan, Richard A ^a   Dudley, Mark E ^a   Cassard, Lydie ^a   Yang, James C ^a   Hughes, Marybeth S ^a   Kammula, Udai S ^a   Royal, Richard E ^a   Sherry, Richard M ^a   Wunderlich, John R ^a   Lee, Chyi Chia R ^a   Restifo, Nicholas P ^a   Schwarz, Susan L ^a   Cogdill, Alexandria P ^a   Bishop, Rachel J ^b   Kim, Hung ^c   Brewer, Carmen C ^c   Rudy, Susan F ^c   VanWaes, Carter ^c   Davis, Jeremy L ^a   Mathur, Aarti ^a   Ripley, Robert T ^a   Nathan, Debbie A ^a   Laurencot, Carolyn M ^a   Rosenberg, Steven A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^d DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RA ANTIGEN; CD45RO ANTIGEN; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MELANOMA ANTIGEN DMF5; RETROVIRUS VECTOR; STEROID; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADULT; ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EAR; EYE; FEMALE; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEARING LOSS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOCYTE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; SKIN; UVEITIS; ADOPTIVE TRANSFER; ANIMAL; AUTOTRANSPLANTATION; CLINICAL TRIAL; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE TRANSFUSION; METABOLISM; METHODOLOGY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ADULT; ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; FEMALE; GENE THERAPY; GENETIC VECTORS; HEARING LOSS; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MELANOCYTES; MELANOMA; MICE; MICE, TRANSGENIC; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; UVEITIS;

EID: 70149114880     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-211714     Document Type: Article

References (32)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91:3515-3519. (Pubitemid 24139460)
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994;91:6458-6462. (Pubitemid 24984961)
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-625.
5. Gallegos AM, Bevan MJ. Central tolerance: good but imperfect. Immunol Rev. 2006;209:290-296.
6. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265.
7. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
8. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
9. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
10. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
11. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
12. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-342. (Pubitemid 36858717)
13. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472.
14. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
15. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high-avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177:6548-6559. (Pubitemid 44628874)
16. Yang S, Cohen CJ, Peng PD, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008;15:1411-1423.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
18. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130. (Pubitemid 39628146)
19. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101:1290-1298. (Pubitemid 36182498)
20. Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 2008;33:517-523.
21. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 1995;92:11993-11997. (Pubitemid 26013997)
22. Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105:8061-8066. (Pubitemid 351904708)
23. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy: how far can we go? Nat Clin Pract Oncol. 2006;3:668-681. (Pubitemid 44843125)
24. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45. (Pubitemid 37328885)
25. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720-724.
26. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426-5435. (Pubitemid 47510370)
27. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114:1774-1781. (Pubitemid 40385533)
28. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110:2620-2630. (Pubitemid 47523186)
29. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
30. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005;174:4415-4423. (Pubitemid 40396025)
31. Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol. 2005;175:5799-5808. (Pubitemid 41508064)
32. Parkhurst M, Joo J, Riley JP, et al. Characterization of genetically modified T cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res. 2009;15:169-180.